Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRELIMINARY FINANCIAL INFORMATION OF TASLY PHARMACEUTICAL FOR THE SIX MONTHS ENDED 30 JUNE 2026

On 14 July 2026, Tasly Pharmaceutical released its unaudited preliminary financial information for the six months ended 30 June 2026.

Tasly Pharmaceutical Group Co., Ltd. (天士力醫藥集團股份有限公司) ("**Tasly Pharmaceuticals**") is a company incorporated in the People's Republic of China. The shares of Tasly Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Tasly Pharmaceutical is owned as to approximately 28% equity interest by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**"), through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (華潤三九醫藥股份有限公司), and is accounted for as a subsidiary of the Company.

On 14 July 2026, Tasly Pharmaceutical released its unaudited preliminary financial information for the six months ended 30 June 2026 (the "**Reporting Period**") (the "**Tasly Pharmaceutical Preliminary Financial Information**"). Set out below are the key financial information of the Tasly Pharmaceutical Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR SIX MONTHS ENDED 30 JUNE 2026 (UNAUDITED)

Unit: RMB ten thousand

Item	**The Reporting Period**	**The corresponding period of previous year**	**Increase/ decrease (%)**
Total operating revenue	420,105.38	428,820.89	–2.03%
Operating profit	104,776.27	91,212.50	14.87%
Total profit	104,633.97	90,461.87	15.67%
Net profit attributable to the shareholders of the listed company	89,268.22	77,469.65	15.23%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	87,053.69	64,004.85	36.01%
Basic earnings per share *(RMB)*	0.60	0.52	15.38%
Weighted average return on net asset *(%)*	6.98%	6.38%	Increase by 0.60%

Item	**As of the end of the Reporting Period**	**As of the beginning of the Reporting Period**	**Increase/ decrease (%)**
Total assets	1,530,176.77	1,533,971.97	–0.25%
Equity attributable to the shareholders of the listed company	1,307,626.00	1,240,422.84	5.42%
Share capital	149,395.00	149,395.00	0.00%
Net assets per share attributable to the shareholders of the listed company *(RMB)*	8.75	8.30	5.42%

Note:

(1) The above information is based on information from unaudited consolidated financial statements. The financial information set out in the 2026 interim report to be published by Tasly Pharmaceutical shall prevail.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

In the first half of 2026, faced with changes in the policy environment of the pharmaceutical industry, Tasly Pharmaceutical, guided by its corporate vision of "innovation-driven to build a leading enterprise in the domestic pharmaceutical industry", and centred around the "15th Five-Year" development strategy, focused on three core therapeutic areas, being cardiovascular and metabolic, neurology and psychiatry, and gastroenterology, and systematically advanced management work across the full chain of R&D innovation, sales and marketing, intelligent manufacturing, and operational management. Tasly Pharmaceutical optimised its business structure and achieved steady improvements in operational efficiency and business quality. During the Reporting Period, Tasly Pharmaceutical achieved total operating revenue of RMB4.201 billion, representing a year-on-year decrease of 2.03%, mainly due to an industry-wide decline in traditional Chinese medicine injectables and a decrease in sales revenue from cold and fever medicines compared to the same period last year, net profit attributable to shareholders of the listed company of RMB893 million, representing a year-on-year increase of 15.23%, and net profit attributable to shareholders of the listed company (excluding extraordinary gains or losses) of RMB871 million, representing a year-on-year increase of 36.01%.

The Tasly Pharmaceutical Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by Tasly Pharmaceutical in its 2026 interim report shall prevail.

The financial information is limited to Tasly Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Tasly Pharmaceutical audited interim financial results, please refer to the interim report for the six months ended 30 June 2026 to be published by Tasly Pharmaceutical on the website of the Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 14 July 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.